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Abstract
Background
The increase in incidence of thyroid cancer during the last decades without concomitant rise
in mortality may reflect the growing detection of indolent forms of thyroid cancer, and may
have fueled unnecessary thyroidectomies. Our aim was therefore, to compare recent secu-
lar trends in surgical intervention rate for thyroid cancer with the incidence and mortality of
thyroid cancer to assess overdiagnosis and resulting overtreatment.
Methods
We conducted a population-based temporal trend study in Switzerland from 1998 to 2012.
All cases of invasive thyroid cancer, deaths from thyroid cancer, and cancer-related thyroid-
ectomies were analyzed. We calculated changes in age-standardized thyroid cancer inci-
dence rates, stratified by histologic subtype and tumor stage, thyroid cancer-specific
mortality, and thyroidectomy rates.
Results
Between 1998 and 2012, the age-standardized annual incidence of thyroid cancer
increased from 5.9 to 11.7 cases/100,000 among women (annual mean absolute increase:
+0.43/100,000/year) and from 2.7 to 3.9 cases/100,000 among men (+0.11/100,000/year).
The increase was limited to the papillary subtype, the most indolent form of thyroid cancer.
The incidence of early stages increased sharply, the incidence of advanced stages
increased marginally, and the mortality from thyroid cancer decreased slightly. There was a
three- to four-fold increase in the age-standardized annual thyroidectomy rate in both sexes.
Conclusions
We observed a large increase in the incidence of thyroid cancer, limited to papillary and
early stage tumors, with a three- to four-fold parallel increase in thyroidectomy. The mortality
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slightly decreased. These findings suggest that a substantial and growing part of the
detected thyroid cancers are overdiagnosed and overtreated.
Impact
Targeted screening and diagnostic strategies are warranted to avoid overdetection and
unnecessary treatment of thyroid cancers.
Introduction
With an estimated 316,000 new cases in 2015, thyroid cancer represents about 2% of all inva-
sive cancers with a large between-country variability [1]. In North America, the age-standard-
ized incidence rate of thyroid cancer was 20.0 cases per 100,000 among women and 6.3 cases
per 100,000 among men in 2012 [1]. Thyroid cancer has an excellent vital prognosis with a
5-year survival rate of above 85% [2, 3]. Over the last few decades, the incidence of thyroid can-
cer has markedly increased in high-income countries [4], including the United States [5],
South Korea [6], the United Kingdom and several European countries [7–11]. It is the cancer
with the fastest increase in frequency and if recent trends are maintained, thyroid cancer will
be the fourth most common cancer by 2030 [12]. Further, in several studies, the increase in
incidence was limited to papillary carcinoma, the most frequent and indolent histological
form of thyroid cancer [10, 13], and the thyroid cancer-specific mortality rate has remained
stable or slightly decreased [4–16]. An increase in incidence largely confined to the more indo-
lent histological subtype and to early tumour stages, without concomitant increase in mortal-
ity, suggests cancer overdiagnosis, that is the detection of indolent cancer forms that will
neither cause symptoms during a persons’ lifetime, nor reduce lifespan [13–18].
Because most thyroid cancers are primarily treated by surgery, i.e., partial or total thyroid-
ectomy [19], overdiagnosis leads to overtreatment through the performance of unnecessary
thyroidectomies without clear benefit for the patient. Incidence and mortality based studies
supporting overdiagnosis [4–18] on the one side, and hospital-based series of increased num-
ber of thyroidectomies performed [20–22] on the other side, have been reported. However, no
study has assessed concomitant trends in the incidence and mortality of thyroid cancer and
related surgery at a population level.
Our aim was therefore to compare recent secular trends in surgical intervention rate for
thyroid cancer with the incidence and mortality of invasive thyroid cancer in Switzerland. Our
hypothesis was that an increase in the incidence of papillary subtype and early-stage thyroid
tumors with a concomitant increase in thyroidectomy rates, but without increase in thyroid
cancer-specific mortality, would provide indirect evidence for thyroid cancer overdiagnosis
and overtreatment.
Materials and methods
Study design
We conducted population-based temporal trend analyses of incidence and mortality rates of
thyroid cancer and of thyroidectomy rates in Switzerland between 1998 and 2012.
Overdiagnosis and overtreatment of thyroid cancer
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Data sources and case definition
1. Registry data for cancer cases and mortality. In Switzerland, registration of cancer is
organized at the regional level with a high level of exhaustivity. Data on all new cancer cases
are collected, documented and recorded by population-based regional cancer registries. The
National Institute for Cancer Epidemiology and Registration (NICER) compiles and aggre-
gates this data (www.nicer.org). Quality control procedures are based on the guidelines from
the European Network of Cancer Registries [23]. In 2012, regional cancer registries covered
68% of the Swiss population and all contributed to this study (cantons Appenzell (Inner and
Ausser), Basel (Stadt and Land), Geneva, Glarus, Graubu¨nden, Jura, Luzern, Neuchaˆtel,
Obwalden and Nidwalden, St. Gallen, Thurgau, Ticino, Uri, Vaud, Valais, Zug and Zu¨rich).
Cancer mortality data based on death reports are collected and checked by the Swiss Federal
Statistical Office (SFSO), and were provided by NICER for this study.
Neoplastic pathologies are coded according to the 3rd edition of the International Classifica-
tion of Diseases for Oncology (ICD-O-3). For our analyses, we used primary invasive thyroid
cancer cases (ICD-O-3: C73) recorded in all cancer registries between 1998 and 2012. Thyroid
cancers were grouped by histological subtype (papillary: ICD-O-3 codes 8050, 8260, 8340,
8341, 8342, 8343, 8344 and 8350; non-papillary: ICD-O-3 codes 8020, 8021, 8030, 8031, 8032,
8033, 8041, 8290, 8330, 8331, 8332, 8335, 8345, 8346, 8347, 8510, 8511 and 8512; rare (<1%)
and unknown types: others/unknown) and tumor stage (early, advanced) according to recent
oncology guidelines using the TNM classification (European Society for Medical Oncology
(ESMO; www.esmo.org), National Comprehensive Cancer Network (NCCN; www.nccn.org),
American Thyroid Association (ATA) [19], TNM (www.uicc.org/resources/tnm)). In persons
younger than 45 years of age, stage I (M0) tumors were defined as early cancer and stage II
(M1) tumors were defined as advanced cancer. In persons aged 45 or older, stage I (T1N0M0)
and stage II tumors (T2N0M0) were defined as early cancer whereas stage III (T3N0M0, T1-
3N1aM0) and stage IV (M1, all anaplastic carcinoma) tumors were defined as advanced cancer
[19].
Trends by stage were limited to Swiss regions for which staging was documented in over
90% of cases each year (Basel-Stadt, Basel-Land, Fribourg, Geneva and Valais) to allow reliable
analyses. By focusing on invasive thyroid cancer cases diagnosed between 1998 and 2012, our
analyses were not affected by the recent histological reclassification of encapsulated follicular
variant of papillary cancer to noninvasive follicular neoplasm with papillary-like nuclear fea-
tures [24].
2. Hospital data for thyroid cancer surgery. Data on thyroid cancer surgery were col-
lected from all Swiss inpatient cases using the SFSO’s Hospital Medical Statistics. Surgical pro-
cedures are registered by a year-specific Swiss Classification of Surgical Interventions (CHOP)
code [25]. Codes are determined by physicians and checked by trained medico-administrative
staff to ensure their accuracy and completeness. In 2012, 99% of all hospitals in Switzerland
were included with a case coverage of 98% of all admissions.
To analyze trends in surgery between 1998 and 2012, we used year-specific diagnostic
ICD-O-3 and CHOP codes. We identified individuals with a diagnosis of invasive thyroid can-
cer (ICD-O-3 code: C73) who had major cancer-related surgery, that is, partial or total thy-
roidectomy (CHOP code: 06.2–06.5; unilateral hemithyroidectomy, other partial
thyroidectomy, total thyroidectomy, substernal thyroidectomy) during the same year.
Assessment of overdiagnosis. There is no direct way to prove that a cancer has been over-
diagnosed unless people are followed without treatment until they die of other causes. Secular
trends incidence and mortality rates can however provide indirect evidence for overdiagnosis
[15]. A substantial and sustained increase in incidence without concomitant increase in
Overdiagnosis and overtreatment of thyroid cancer
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mortality of, and accordingly a parallel increase in surgery for, thyroid cancer are indirect evi-
dence of overdiagnosis and resulting overtreatment, respectively. A substantial and sustained
increase in incidence of early stage cancer without an increase in the incidence of advanced
stage cancer can also be suggestive of overdiagnosis.
Statistical analyses. Rates were age-standardized to the European standard population.
We computed annual thyroid cancer incidence rates stratified by sex, histological subtype, and
tumour stage. We further computed annual thyroid cancer mortality rates and thyroidectomy
(partial or total) rates stratified by sex. To smooth estimates, we computed absolute differences
in using pooled data from the first three years (1998–2000) and the last three years (2010–2012).
We fitted a linear regression model to estimate the annual mean absolute and relative changes
in the standardized rates with calendar year as predictor variable. Joinpoint statistical software
(version 4.3; Surveillance Research Program, National Cancer Institute, Bethesda, MD) was
used to identify and estimate the parameters of the linear model and to test for statistical signifi-
cance. In Joinpoint, we used the grid search method and provided standard errors to adjust for
heterosedascticity. To account for the possibility of incomplete recording in the three first years
of the study period, a set of sensitivity analyses were conducted omitting data collected between
1998 and 2000. Statistical analyses were performed with STATA (version 13) and R-studio.
Ethics. Anonymised and publicly available aggregated data were used for our analyses.
There was no threat to patient confidentiality. According to the Swiss Human Research Act
(Humanforschungsgesetz HFG), no ethical approval or trial registration is needed for such
analyses. Our study protocol was agreed upon by NICER. The SFSO allowed the analyses and
publication of deidentified hospital data (contract 150 556).
Results
Between 1998 and 2012, 4,907 cases of thyroid cancer (women: 3,642; men: 1,265) were regis-
tered and analyzed. The total number of cases by year, sex, and histological subtype are
reported in S1 Table. The age-standardized incidence rate of thyroid cancer was about three
times higher in women than in men (Fig 1 panel A and B; Tables 1 and 2). Between 1998 and
2012, it increased by 7% per year in women, corresponding to an absolute mean annual change
of +0.43/100,000 women (95% CI: 0.37 to 0.49) (Table 3). During the same time period, the
incidence of thyroid cancer increased by 4% per year in men, corresponding to an absolute
mean annual change of +0.11/100,000 men (95% CI: 0.07 to 0.15).
The increase in incidence was essentially due to an increase in the papillary subtype (Fig 1
Panel A, B; Table 1). Between 1998 and 2012, the age-standardized incidence of papillary car-
cinoma increased by 10% per year in women, corresponding to an annual mean change of
+0.41/100,000 women (95% CI: 0.35 to 0.47). In men, the incidence increased by 8% per year,
corresponding to an annual mean change of +0.11/100,000 men (95% CI: 0.08 to 0.15). In
both sexes, there was no substantial change in the incidence of other histologic subtypes of thy-
roid cancer (Table 3).
The absolute increase in the incidence of early stages of thyroid cancer was large, especially
in women (Tables 2 and 3). No statistically significant increase was observed for advanced
stages in women, while a small absolute increase was observed in men.
Between 1998 and 2012, 592 deaths from thyroid cancer (women 397; men: 195) occurred.
In contrast to the rising incidence, the thyroid cancer-related mortality slightly decreased in
both sexes (Fig 1 Panel A, B; and Table 1). In women, the age-standardized mortality rate
decreased by 3% per year, corresponding to an annual mean absolute change of -0.02/100,000
women (95% CI: -0.03 to -0.01). In men, the mortality rate decreased by 2% per year, corre-
sponding to annual mean absolute change of -0.01/100,000 men (95% CI: -0.02 to 0.00).
Overdiagnosis and overtreatment of thyroid cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0179387 June 14, 2017 4 / 12
Between 1998 and 2012, 6,419 cases of thyroidectomy (women: 4,763; men: 1,656) were reg-
istered in Switzerland (S2 Table). In both sexes, a large increase in the rate of thyroidectomy
was observed (Fig 1 Panel C, D; and Table 1). The age-standardized rate of thyroidectomy
increased yearly by 17% in women, corresponding to an annual mean absolute change of
+0.59/100,000 women (95% CI: 0.53 to 0.64), and by 15% in men, corresponding to an annual
mean absolute change of +0.20/100,000 men (95% CI: 0.17 to 0.23) (Table 3).
Discussion
Our study demonstrates a large rise in the incidence of thyroid cancer, confined to papillary
carcinoma and early stage tumors, with a concomitant three- to four-fold increase in the rate
of thyroidectomy and a slight decrease in thyroid cancer mortality in Switzerland between
1998 and 2012. These findings suggest that a substantial and growing part of the detected thy-
roid cancers are overdiagnosed and overtreated.
Fig 1. Age-standardized incidence and age-standardized mortality rates for thyroid cancer in women (A) and men (B). Age-standardized rate of
thyroidectomy in women (C) and men (D), Switzerland, 1998–2012. Data source: National Institute of Cancer Epidemiology and Registration (NICER)
and Swiss Federal Statistical Office (SFSO) Hospital Medical Statistics.
https://doi.org/10.1371/journal.pone.0179387.g001
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Our results are consistent with several studies showing a rapidly increasing thyroid cancer
incidence without a substantial change or a slight decrease in mortality in high-income coun-
tries [4, 7–11, 16, 26, 27]. In recent analyses comparing expected versus observed incidence,
45% to 70% of thyroid cancer cases were considered as overdiagnosed in France, South Korea,
the United Kingdom and the United States [28]. The magnitude of our observed increase in
the incidence of thyroid cancer over the last 15 years in Switzerland is close to the reported
increase in the United States, but far less than in South Korea, where thyroid cancer screening
with ultrasonography as health checkup is commonly performed by general practitioners since
1999 [6]. Trend analyses of thyroid cancer surgery are however much rarer [20–22, 29]. In the
United States, hospital data revealed a 31% increase in the number of total thyroidectomies or
lobectomies performed for thyroid nodule-related diagnoses between 2006 and 2011 [20].
Another report using discharge data from the Nationwide Inpatient Sample showed a 39%
increase in the number of thyroid surgical cases for benign and malignant diseases between
1993 and 2008 with a growing proportion of operations performed for cancer [29]. In Illinois,
the rate of thyroidectomies increased by 44% from 1999 to 2009 [21]. However, these rates
were not age-standardized. A study from Belgium showed a correlation between thyroid sur-
gery of any indication (mainly goiters) and detection of low-risk thyroid cancer after histologic
work-up [30]. To our knowledge, our study is the first to report nationwide, population-based,
and age-standardized estimates of the incidence of thyroid cancer and concomitant related
surgery.
Table 1. Age-standardized (European population) incidence rates, mortality rates, and thyroidectomies for thyroid cancer per 100’000 inhabitants,
by year and sex. Switzerland, 1998–2012. Incidences are also reported by histological subtypes.
Year Women Men
Incidence Mortality Thyroidectomies Incidence Mortality Thyroidectomies
Papillary Non-
papillary
All
cases
All cases All cases Papillary Non-
papillary
All
cases
All cases All cases
1998 4.07 1.79 5.86 0.67 2.68 1.59 1.15 2.74 0.56 1.27
1999 4.40 1.90 6.30 0.76 4.06 1.21 0.80 2.02 0.36 1.29
2000 5.06 2.18 7.24 0.59 4.34 1.82 1.05 2.88 0.71 1.39
2001 4.18 2.24 6.42 0.85 4.98 1.31 1.27 2.58 0.78 2.33
2002 5.51 1.72 7.23 0.74 6.11 1.50 1.34 2.84 0.48 2.00
2003 5.89 1.80 7.69 0.69 6.36 1.90 0.80 2.70 0.50 2.06
2004 6.03 1.59 7.62 0.61 6.99 1.57 1.47 3.04 0.53 2.61
2005 6.16 2.10 8.26 0.64 7.84 2.74 1.05 3.80 0.33 3.19
2006 6.61 1.66 8.27 0.43 7.44 2.71 0.84 3.55 0.52 2.94
2007 6.64 2.24 8.88 0.62 9.12 2.80 1.43 4.24 0.40 3.30
2008 8.81 2.23 11.04 0.34 9.86 1.92 0.85 2.77 0.31 2.89
2009 9.14 1.79 10.93 0.42 9.33 2.93 1.05 3.97 0.43 3.26
2010 7.74 2.55 10.29 0.57 8.91 2.67 1.62 4.29 0.44 3.79
2011 9.88 2.04 11.93 0.50 11.21 2.38 0.78 3.16 0.34 3.63
2012 9.61 2.10 11.71 0.48 11.61 2.93 0.95 3.88 0.42 4.00
Absolute change
1998–2000 vs 2010–
2012
+4.6 +0.2 +4.9 -0.2 +6.88 +1.1 +0.1 +1.2 -0.2 +2.49
Relative change
1998–2000 vs 2010–
2012
+102% +13% +75% -24% +186% +73% +13% +48% -27% +189%
Data source: National Institute of Cancer Epidemiology and Registration (NICER) and Swiss Federal Statistical Office (SFSO), Hospital Medical Statistics.
https://doi.org/10.1371/journal.pone.0179387.t001
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We cannot exclude that unfavorable trends in risk factors for thyroid cancer could explain
our observations. Radioactive exposure is a major risk factor, particular for papillary thyroid
cancer [31]. Despite an increase in exposure from medical conditions, the overall radiation bur-
den in Switzerland has declined following broad surveillance and protection measures [32]. The
impacts on thyroid cancer rate of the nuclear power plant accident of Chernobyl in 1986 are dif-
ficult to assess. After this disaster, an increase in thyroid cancer was reported among children
and adolescents exposed to radioactive iodine in Belarus, Russia, and the Ukraine [33]. In Swit-
zerland, it was estimated that the impact of this accident on cancer in Switzerland was rather
low, with an estimated 200 cases of additional cancer deaths of all types and with unknown
effect on thyroid cancers [34]. Such an effect could not explain the large increase in the number
of thyroid cancers observed in our study. Shortly after the Fukushima Daiichi nuclear plant
accident in 2011, screening with thyroid ultrasound examination was implemented [35]. There
was a large increase in the detection of thyroid cancer. However, this increase has been attrib-
uted mainly to overdiagnosis caused by the screening itself, as the time lag between the exposure
and the increase in the incidence was very short, and as there was no direct correlation between
the increase in the incidence and the regional level of radiation exposure [36].
Another risk factor for thyroid cancer is iodine deficiency, predisposing to goiter and for-
mation of thyroid nodules. In Switzerland, the salt is iodized since 1922 to ensure sufficient
supply. Obesity and other factors related to diet and environment, hormones and genetic back-
ground are inconsistently reported risk factors for thyroid cancer and unlikely to influence
materially our results, but cannot be excluded. However, it would be difficult to explain how a
change in any of these risk factors would increase only the frequency of early stage cases or
indolent forms of thyroid cancer without increasing the incidence of advanced stage cases and
the mortality rate. Changes in histopathologic diagnostic criteria for thyroid cancer in 1988 led
Table 2. Age-standardized (European population) incidence rates for thyroid cancer, per 100’000 inhabitants, by year, sex and stage, Switzerland,
1998–2012.
Year Women
Incidence
Men
Incidence
Early Advanced Early Advanced
1998 6.41 1.49 1.30 0.97
1999 6.58 1.26 1.29 0.65
2000 5.50 1.85 1.80 1.07
2001 5.06 1.91 1.19 0.65
2002 5.76 1.20 1.83 0.61
2003 6.86 1.96 2.30 0.93
2004 7.22 1.21 1.90 1.57
2005 9.01 1.28 3.66 1.27
2006 6.29 1.26 3.67 0.95
2007 7.69 1.16 3.66 1.98
2008 9.76 2.16 2.63 1.26
2009 11.18 2.47 2.69 2.15
2010 9.90 1.39 3.16 1.55
2011 12.15 1.28 1.73 0.99
2012 12.46 2.44 2.86 1.12
Absolute change 1998–2000 vs 2010–2012 + 5.34 + 0.18 + 1.12 + 0.33
Relative change 1998–2000 vs 2010–2012 + 87% + 12% + 76% + 37%
Data source: National Institute of Cancer Epidemiology and Registration (NICER), limited to 5 regions (cf. Methods section).
https://doi.org/10.1371/journal.pone.0179387.t002
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to a spurious upward trend in incidence in one Swiss region, but seemed unlikely to affect our
study period [32, 37].
The most likely cause of the rise in the incidence of thyroid cancer is increasing detection
due to incidental findings through advanced imaging and the systematic diagnostic explora-
tion of small thyroid nodules. Autopsy studies have shown that there is a large reservoir of sub-
clinical papillary thyroid cancers [38]. Three mechanisms have been identified to explain the
growing number of thyroid cancer diagnosed: opportunistic screening (by physical examina-
tions of the thyroid in asymptomatic patients), diagnostic cascade (through performance of
multiple tests to evaluate vague complaints) and incidental findings (through detection of thy-
roid abnormalities on radiological examinations not performed to examine the thyroid) [5].
Although there are no recommendations to screen systematically for thyroid cancer in Swit-
zerland, ultrasonography and guided fine-needle biopsy in patients with thyroid nodules are
commonly performed. The high availability of advanced imaging (computed tomography
(CT) scanners and Magnetic Resonance Imaging (MRI) units) per inhabitant in Switzerland
(www.oecd.org) facilitates the prescription, e.g., of neck MRI or chest CT with the resulting
risk of incidental findings of thyroid nodules and, eventually, of thyroid cancer [38]. Had thy-
roid cancer incidence remained at the level of 1998 in Switzerland and assuming that all the
Table 3. Trends in the incidence and mortality of thyroid cancer and in the incidence of thyroidectomy, 1998–2012; Switzerland. All rates are
directly standardized on the European population. CI: confidence interval.
Women Men
Absolute annual mean
change in rate [per
100’000]
95% CI [per
100’000]
Relative
increase per
year
95% CI
[%]
Absolute annual mean
change in rate [per
100’000]
95% CI [per
100’000]
Relative
increase per
year
95% CI
[%]
Incidence + 0.43 0.37 to 0.49 + 7% 6% to
8%
+ 0.11 0.07 to 0.15 + 4% 3% to
6%
Incidence by
histologic typea
Papillary + 0.41 0.35 to 0.47 + 10% 9% to
12%
+ 0.11 0.08 to 0.15 + 8% 6% to
11%
Non-papillary + 0.02 0.00 to 0.04 + 1% 0% to
2%
0.00 -0.03 to 0.02 - 1% - 2% to
2%
Other/unknown + 0.01 -0.01 to 0.02 0% - 2% to
7%
+ 0.01 0.00 to 0.02 + 17% - 9% to
44%
Incidence by
stageb
Early + 0.47 0.32 to 0.62 + 9% 6% to
12%
+ 0.11 0.04 to 0.19 + 7% 3% to
13%
Advanced + 0.02 -0.03 to 0.06 + 1% - 2 to
4%
+ 0.05 0.02 to 0.09 + 6% 2% to
11%
Unknown 0.00 0.00 to 0.01 0% - 0.00 0.00 to 0.00 0% -
Mortalitya - 0.02 -0.03 to
-0.01
- 3% - 4% to
- 2%
- 0.01 -0.02 to 0.00 - 2% - 4% to
- 2%
Surgery
incidencec
Thyroidectomy + 0.59 0.53 to 0.64 + 17% 16% to
19%
+ 0.20 0.17 to 0.23 + 15% 13% to
17%
Data sources:
aNational Institute of Cancer Epidemiology and Registration (NICER);
bNICER limited to 5 regions (cf. Methods section);
cSwiss Federal Statistical Office (SFSO), Hospital Medical Statistic
https://doi.org/10.1371/journal.pone.0179387.t003
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increase in the incidence was due to overdiagnosed cases, then at least one third of thyroidec-
tomies could be unnecessarily performed each year in Switzerland.
The slight decrease in thyroid cancer-specific mortality over time may reflect improved
treatment strategies, thanks e.g. to refined surgical techniques with a lower complication rate
and better post-surgical care. In contrast to our observations, Lim et al. recently described an
increase in the overall incidence of thyroid cancer and related mortality in the US, such find-
ings being consistent with a true (not only due to overdiagnosis) increase in thyroid cancer
[39]. However, the absolute increase in mortality was very small compared with the huge
increase in incidence, which points to a large contribution of overdiagnosis to the increasing
incidence, as acknowledged by the authors. The increase in mortality could also indicate a
worsening in quality of care and outcome of thyroid cancer surgery.
Our study has several strengths. First, our analyses rely on population-based and high quality
data, including cancer registries and hospital-based statistics covering a large proportion of the
population. Second, we analyzed trends in thyroid cancer and surgery for thyroid cancer during
the same time period to compare incidence, mortality and surgery rates at a whole population
level. However, our study has several limitations. As a time trend analysis, it can provide only
indirect evidence of overdiagnosis and overtreatment. There is no direct way to prove that a
cancer is overdiagnosed unless patients are followed untreated until they die of other causes
[15–18]. Although the Swiss population coverage by cancer registries was not nationwide, to
the best of our knowledge, there is no reason to believe that thyroid cancer trends differ sub-
stantially across regions in particular by histological type or stage. Thus, the restriction of tumor
stage analyses to regions for which staging was nearly systematically documented (over 90% of
cases each year) appears unlikely to alter substantially our results. Also, we cannot exclude that
surgery coding practices may differ between hospitals and change across time. These are general
and well-known issues of studies using medico-administrative data [40]. To minimize this risk,
we have taken into account changes of coding procedures for thyroid surgery over time using
year-specific codes. Further, as thyroid surgeries are major procedures performed as inpatient
intervention, the probability of cases not being registered and coded is very low.
In conclusion, our study provides indirect evidence of overdiagnosis and overtreatment of
thyroid cancer. It appears that a substantial number of thyroid cancers that were never des-
tined to cause symptoms in a person’s life are detected and treated with potentially unneces-
sary surgery and considerable long-term consequences and risk of complications.
Examination of the mechanisms that drive overdiagnosis and overtreatment of thyroid cancer
is urgently warranted. Due notably to the harms of overdiagnosis, the US Preventive Services
Task Force has recently updated its recommendation against routine screening for thyroid
cancer (D level recommendation) [38, 41]. To identify which patients could benefit from the
detection of early stage cases, a risk-based screening with combined diagnostic and prognostic
tools (biomarker, personalized medicine) could be a promising approach to tailor prevention
and screening according to the individual risk of thyroid cancer [42]. Further, active surveil-
lance of incidental, asymptomatic and small papillary thyroid cancers should be seriously con-
sidered and tested in adequately designed clinical studies [7]. Meanwhile, patients should be
informed of the overall excellent prognosis of the great majority of small papillary thyroid can-
cers, as well as of the uncertainties in our ability to identify “high risk” cancers [43].
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